Is US Preparing For A Quademic 2025?

Updated Jan 15, 2025 | 03:10 PM IST

SummaryQuademic 2025: It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.
Is US preparing for a quademic?

Credits: Canva

Quademic 2025: Hospitals in the United States are dealing with a surge in patients admission, the reason is the quademic it is dealing with at this moment. This has led to an influx of patients. It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.

The healthcare company founded in academics M Health Fairview, confirmed that their hospitals are overflowing due to the quademic.

Is US able to cope with Quademic 2025?

The hospitals of M Health Fairview's volume is up by 30% and as a results, patients are being treated in the hallways and in alternative care areas. There is also a longer wait time and shortages for resources that are required to treat these emergencies. This has also impacted other life-threatening emergencies like heart attacks and strokes, as the healthcare resources and caregivers are occupied with the surge in seasonal cases.

ALSO READ: Birmingham Struggles With 4 Different Virus Hits, Know What They Are

What are these quademic infections?

Common cold and flu: The common cold and influenza (flu) are perhaps the most well-known illnesses that peak during the fall. As temperatures drop and humidity levels fluctuate, viruses that cause colds and the flu become more active. The flu, in particular, can be more severe than a common cold, leading to complications such as pneumonia, especially in vulnerable populations like the elderly and those with pre-existing health conditions. Symptoms include a runny nose, sore throat, coughing, fever, and body aches.

Covid-19: As per the World Health Organization, Coronavirus disease or COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with this virus will experience mild to moderate respiratory illness and recover without requiring special treatment, However, there could be some cases of seriously ill patients who may require medical attention. It is also because of the other existing medical conditions like cardiovascular diseases, diabetes, chronic respiratory diseases, cancers, or older age.

The best way to protect against this virus is by following social isolation form those who are infected, using mask to prevent droplets from infecting others when you cough or sneeze and to wash your hands for 20 seconds frequently.

RSV or Respiratory Syncytial Virus: As per the Centers of Diseases Control and Prevention (CDC), RSV is a common respiratory virus that infects nose, throat and lungs. Though symptoms are similar to the viruses like flu or COVID-19, the disease in itself is different. It also peaks during the winter season, especially between December and January.

However, the main difference between RSV and other respiratory illness, above mentioned is that RSV can cause pneumonia or bronchiolitis, especially for those who are over the age of 50 or with an existing heart or lung disease.

Norovirus: It is a number 1 cause of foodborne illness in the US and this happens when virus gets into the food and then it accidentally enters your mouth. These particles are from faeces or vomit from infected people, or can be transmitted via contaminated food and water. It could also spread by touching unclean surfaces like door handles or cutlery.

For most people, having norovirus is unpleasant, but mild and recovery could be made in 1 to 2 days. However, it could be more serious for babies, older people and anyone with any existing health condition.

End of Article

Ebola: Suspected Cases in DR Congo Drop To 116 After Hundreds Ruled Out Of Infection, Says WHO

Updated Jun 3, 2026 | 02:02 PM IST

SummaryThe WHO explained that the latest figures were significantly lower because hundreds of suspected cases had been discounted after further investigation.
Ebola: Suspected Cases in DR Congo Drop To 116 After Hundreds Ruled Out Of Infection, Says WHO

Credit: iStock

In a major relief amid the ongoing Ebola outbreak, the World Health Organization (WHO) said the number of suspected cases has dropped to 116 after hundreds were ruled out following investigation.

Earlier, the number of suspected cases had neared 1,000 in the Democratic Republic of Congo (DRC).

The global health agency said on Tuesday that there had been 48 deaths and six recoveries in Congo, Reuters reported.

In Uganda, there have been nine confirmed cases and one associated death, WHO spokesperson Christian Lindmeier told reporters in Geneva.

Later, Uganda's Ministry of Health confirmed six additional Ebola cases, bringing the country's total number of confirmed infections to 15.

The ministry said in a statement on X that all six newly confirmed cases were among contacts of previously confirmed patients.

Hundreds Of Suspected Cases Ruled Out

Lindmeier explained that the latest figures were significantly lower because hundreds of suspected cases had been discounted after further investigation.

"They have been cleared out and have either other diseases or have just had a fever and nothing else," he said.

Lindmeier added that the numbers would continue to fluctuate as more people are tested.

A suspected case includes anyone identified through surveillance systems or presenting with symptoms at a health facility. Confirmed cases include only those who test positive for the Bundibugyo strain of Ebola.

Last week, the WHO reported 906 suspected Bundibugyo Ebola cases in Congo, including 223 suspected deaths under investigation.

Subsequently, Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention, told the Financial Times that more than 1,100 suspected cases were being investigated.

Testing has posed a major challenge during the outbreak because the commonly used Ebola diagnostic tests initially failed to detect the Bundibugyo strain, for which there is currently no approved vaccine.

Meanwhile, the US Centers for Disease Control and Prevention (CDC) website also listed 116 suspected cases and noted: "On May 29, the DRC Ministry of Health updated their total suspect case count to remove suspected cases that have been ruled out after investigation and suspected deaths that are pending the results of ongoing investigation."

Kenyans Protest Proposed US Ebola Treatment Facility

Also read: Western Australia Records 22 Mpox Infections In 2026; Seven Reported Last Week

The United States' plan to establish an Ebola treatment facility in Kenya has sparked public concern about cross-border infection risks and triggered protests.

The proposed 50-bed isolation centre would be staffed by US medical personnel and is intended to treat US citizens affected by the Ebola outbreak in the Democratic Republic of Congo.

Asked about the proposal during a White House briefing, Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, said keeping affected Americans closer to the outbreak zone would help speed up treatment.

"You have a golden hour in many of these instances around trauma, but for illnesses, it’s also relatively short, so we are confident, and the State Department’s working on this diligently, that they are going to be able to work out something with Kenya. There has already been a fair amount of communication around this issue," Oz said.

Although Kenya has not recorded any Ebola cases, the proposed quarantine facility has raised fears among residents who believe it could increase the risk of exposure to the virus.

End of Article

John Barnes, Bobby Davro Diagnosed With Prostate Cancer Even As UK Rules Out Universal Screening

Updated Jun 3, 2026 | 12:48 PM IST

Summary​Despite the high burden of disease, the UK currently has no national prostate cancer screening program because of concerns over the accuracy of PSA tests. However, there has been growing pressure in recent years to introduce routine screening.
John Barnes, Bobby Davro Diagnosed With Prostate Cancer Even As UK Rules Out Universal Screening

Credit: Instagram

Prostate cancer is the most common cancer among men in the UK. The country records around 55,000 new prostate cancer cases and nearly 12,000 deaths every year.

Although the UK recently ruled out universal prostate cancer screening, opting instead for targeted screening of high-risk men, new cases continue to emerge every day. The latest high-profile figures diagnosed with the disease are former Liverpool winger John Barnes and comedian Bobby Davro.

John Barnes Calls Prostate Cancer A ‘Taboo Subject’

Barnes revealed that he had his prostate removed following a cancer diagnosis and described the condition as a "taboo subject" for men.

"Not many people know and it’s a bit of a taboo subject because we support women with breast cancer and it’s not even an issue," he told Times Radio.

Barnes stressed that "a lot of men don’t want to admit it or want to have it done because it makes them feel less than a man."

He added: "Men have to bite the bullet and swallow their pride and admit if they have problems."

Also read: Jill Biden Opens Up About Joe Biden’s Lifelong Cancer Battle

Bobby Davro Reveals Symptom Before Diagnosis

Meanwhile, 67-year-old Bobby Davro spoke on This Morning about his diagnosis, revealing that he had experienced erectile dysfunction beforehand.

Speaking on the ITV show, Davro said: "I think one in eight men get it. I think a lot of men of color, they get more prostate cancer, so it’s got to be checked.

"So go along and have your PSA (Prostate-Specific Antigen) checked, have the old prostate examined."

Davro continued: "He [the doctor] said: 'It’s a bit swollen, I think you should go and have a PSA test.' And it was 24, which wasn’t good at all."

"Not really. The only thing I had was erectile dysfunction. It wasn’t nice. I tried taking the blue pills. I realised something wasn’t quite right," he said about symptom before diagnosis.

Many other high-profile figures have been diagnosed with prostate cancer, including former UK Prime Minister David Cameron, BBC radio host Bob Harris, and six-time Olympic gold medalist Chris Hoy.

Despite the high burden of disease, the UK currently has no national prostate cancer screening program because of concerns over the accuracy of PSA tests. However, there has been growing pressure in recent years to introduce routine screening.

Read More: Benjamin Netanyahu Undergoes Treatment For Early-stage Prostate Cancer

What Do The New Guidelines Say?

After reviewing the latest evidence, the National Screening Committee (NSC) recommended against broad population-wide screening for prostate cancer.

The committee said the harms of screening outweigh the benefits for most groups. The final guidance states that routine screening should not be offered to:

  • All men
  • Black men, despite their risk being nearly double that of the general population
  • Men with a family history of prostate cancer, as the disease is common enough that family history alone does not sufficiently narrow risk

Who Is Eligible For Targeted Screening?

Instead, the NSC recommends:

  • Targeted prostate cancer screening involving PSA testing every two years for men aged 45 to 61
  • Screening only for men who carry a pathogenic BRCA2 gene variant
  • Screening for those who also have a family history of breast, ovarian, pancreatic, or prostate cancer

Symptoms To Watch For

The prostate is a small walnut-shaped gland in men that produces seminal fluid, which nourishes and transports sperm. Prostate cancer develops when abnormal cells begin growing in the gland.

Common symptoms include:

  • Blood in the urine or semen
  • Difficulty urinating
  • Erectile dysfunction
  • Reduced force in the urine stream
  • Bone pain
  • Unexplained weight loss.

End of Article

Alkem Launches India's First Single-Shot Semaglutide Pre-Filled Syringes At Rs 350

Updated Jun 3, 2026 | 12:51 PM IST

SummaryAlkem noted that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.
Alkem Launches India's First Single-Shot Semaglutide Pre-Filled Syringes At Rs 350

Credit: iStock

Alkem Laboratories today announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths, with prices starting at Rs 350.

The company, in a statement, said it is the first in India to introduce semaglutide in a single-shot pre-filled syringe format for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

Also Read: John Barnes, Bobby Davro Diagnosed With Prostate Cancer Even As UK Rules Out Universal Screening

The ready-to-use format will expand treatment options for patients while lowering entry barriers through affordable pricing.

“Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced,” said Dr. Vikas Gupta, Chief Executive Officer of Alkem Laboratories.

“In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy,” he added.

Alkem noted that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes.

Also read: India To Tighten Regulation For Semaglutide, Other GLP-1 Drugs

The launch follows Alkem’s introduction of semaglutide in pre-filled disposable and reusable injection pen formats in the Indian market in March 2026. The company has also secured regulatory approval for semaglutide vials, which it plans to launch soon.

Meanwhile, domestic peers such as Torrent Pharma and Dr Reddy’s have also introduced non-infringing tablets, with Lupin, Sun Pharma and several others expected to follow suit.

Semaglutide: Risks Vs Benefits

In people with type 2 diabetes, Harvard Health noted that the body's cells are resistant to the effects of insulin and the body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

Notably, semaglutide is not just a glucose-lowering drug, it improves weight and has proven cardiovascular, liver, and renal benefits.

Read More: Pairing Ozempic With Exercise Is Beneficial For Your Muscles, Study Finds

Wider availability could therefore help reduce long-term complications such as heart disease and kidney failure. If used appropriately, this could indeed be a major step forward in total metabolic care, the experts said.

“The increasing affordability of GLP-1 receptor agonists is a double-edged development. On one hand, it significantly improves access for patients with obesity, type 2 diabetes, and high cardiovascular risk, conditions that are highly prevalent in India. These drugs have demonstrated meaningful benefits in weight reduction, glycemic control, and even cardiovascular risk reduction, which could translate into long-term public health gains,” Dr Vivek Bindal, Senior Director & Head, Bariatric and Robotic Surgery, at Max Healthcare, told HealthandMe.

End of Article